Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Site search
Search
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscription Services
Promote Your Event
Submission Forms
Place an Ad
Weather
News
Local News
Sports
Entertainment
Obituaries
Photos
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Items For Sale
Jobs
Pets
Auctions, Estate & Garage Sales
Place an ad
Services
Community
Personals
Best of 2022
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by GlycoMimetics, Inc.
GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687
September 06, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 17, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023
August 02, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics to Report Second Quarter 2023 Financial Results on August 2, 2023
July 19, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Announces Its Addition to the Russell Microcap® Index
June 26, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Announces U.S. Food and Drug Administration Clears Addition of Time-based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia
June 15, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics to Participate in Upcoming Jefferies 2023 Healthcare Conference
May 31, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Reports Highlights and Financial Results for First Quarter 2023
May 03, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics to Report First Quarter 2023 Financial Results on May 3, 2023
April 26, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2022
March 29, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics to Report Fourth Quarter and 2022 Full Year Financial Results on March 29, 2023
March 16, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics to Participate in Upcoming Cowen 43rd Annual Health Care Conference
March 01, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 16, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Announces Continuation of Phase 3 Study of E-selectin Antagonist Uproleselan in Relapsed/Refractory AML to Originally Planned Final Analysis Following Interim Analysis by Independent Data Monitoring Committee
February 15, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
February 06, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia presented at ASH Annual Meeting
December 12, 2022
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2022
November 09, 2022
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics to Participate in Two Upcoming Investor Conferences
November 08, 2022
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia Will Be Presented at ASH Annual Meeting
November 03, 2022
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics to Report Third Quarter Financial Results on November 9, 2022
November 02, 2022
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
September 09, 2022
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics to Participate in Upcoming H.C. Wainwright 24th Annual Global Investment Conference
September 07, 2022
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Appoints Edwin Rock, M.D., Ph.D. as Chief Medical Officer
September 06, 2022
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2022
August 03, 2022
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics to Report Second Quarter Financial Results on August 3, 2022
July 27, 2022
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics to Participate at Upcoming Jefferies 2022 Healthcare Conference
June 02, 2022
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Reports Highlights and Financial Results for First Quarter 2022
April 28, 2022
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics to Report First Quarter Financial Results on April 28, 2022
April 25, 2022
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics to Report Fourth Quarter and 2021 Year-End Financial Results on March 3, 2022
February 25, 2022
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.